Creative Planning’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$59.6M Buy
2,122,972
+271,983
+15% +$7.24M 0.04% 187
2025
Q4
$46.1M Buy
1,850,989
+205,112
+12% +$5.17M 0.03% 213
2025
Q3
$41.9M Buy
1,645,877
+39,190
+2% +$967K 0.03% 218
2025
Q2
$38.9M Sell
1,606,687
-87,607
-5% -$2.04M 0.03% 212
2025
Q1
$42.9M Buy
1,694,294
+130,106
+8% +$3.4M 0.04% 191
2024
Q4
$41.5M Sell
1,564,188
-256,543
-14% -$6.96M 0.04% 171
2024
Q3
$52.7M Buy
1,820,731
+266,167
+17% +$7.76M 0.05% 133
2024
Q2
$43.5M Buy
1,554,564
+182,950
+13% +$5.04M 0.05% 156
2024
Q1
$38.1M Buy
1,371,614
+10,488
+0.8% +$291K 0.04% 169
2023
Q4
$39.2M Sell
1,361,126
-110,898
-8% -$3.35M 0.07% 152
2023
Q3
$48.8M Buy
1,472,024
+60,660
+4% +$2.15M 0.07% 126
2023
Q2
$51.8M Buy
1,411,364
+62,912
+5% +$2.45M 0.07% 112
2023
Q1
$55M Buy
1,348,452
+10,106
+0.8% +$436K 0.08% 107
2022
Q4
$68.6M Buy
1,338,346
+82,401
+7% +$3.95M 0.1% 96
2022
Q3
$55M Sell
1,255,945
-15,377
-1% -$747K 0.1% 93
2022
Q2
$66.7M Buy
1,271,322
+140,167
+12% +$7.14M 0.11% 86
2022
Q1
$58.6M Buy
1,131,155
+69,894
+7% +$3.63M 0.09% 97
2021
Q4
$62.7M Buy
1,061,261
+13,226
+1% +$655K 0.1% 78
2021
Q3
$45.1M Sell
1,048,035
-17,732
-2% -$786K 0.08% 101
2021
Q2
$41.7M Buy
1,065,767
+79,653
+8% +$3.1M 0.07% 105
2021
Q1
$35.7M Sell
986,114
-52,879
-5% -$1.88M 0.07% 105
2020
Q4
$38.2M Buy
1,038,993
+38,290
+4% +$1.4M 0.08% 97
2020
Q3
$34.8M Buy
1,000,703
+95,355
+11% +$3.34M 0.09% 91
2020
Q2
$28.1M Buy
905,348
+21,359
+2% +$726K 0.08% 97
2020
Q1
$27.4M Sell
883,989
-35,586
-4% -$1.21M 0.1% 85
2019
Q4
$34.2M Sell
919,575
-26,486
-3% -$943K 0.1% 86
2019
Q3
$32.3M Sell
946,061
-19,607
-2% -$713K 0.11% 85
2019
Q2
$39.7M Sell
965,668
-556
-0.1% -$22.1K 0.13% 70
2019
Q1
$38.9M Sell
966,224
-2,303
-0.2% -$92.2K 0.14% 66
2018
Q4
$40.1M Sell
968,527
-12,004
-1% -$498K 0.16% 57
2018
Q3
$41M Buy
980,531
+90,746
+10% +$3.49M 0.15% 60
2018
Q2
$30.6M Buy
889,785
+65,022
+8% +$2.22M 0.12% 70
2018
Q1
$27.8M Buy
824,763
+10,361
+1% +$356K 0.11% 75
2017
Q4
$28M Buy
814,402
+28,801
+4% +$982K 0.12% 74
2017
Q3
$26.6M Buy
785,601
+5,894
+0.8% +$189K 0.12% 76
2017
Q2
$24.8M Sell
779,707
-17,331
-2% -$547K 0.13% 78
2017
Q1
$25.9M Sell
797,038
-53,422
-6% -$1.68M 0.14% 71
2016
Q4
$26.2M Buy
850,460
+70,182
+9% +$2.14M 0.16% 67
2016
Q3
$25.1M Buy
780,278
+70,702
+10% +$2.36M 0.16% 65
2016
Q2
$23.7M Buy
709,576
+35,086
+5% +$1.12M 0.17% 58
2016
Q1
$19M Sell
674,490
-21,894
-3% -$625K 0.15% 67
2015
Q4
$21.3M Buy
696,384
+94,531
+16% +$2.97M 0.18% 62
2015
Q3
$17.9M Buy
601,853
+5,558
+0.9% +$178K 0.16% 68
2015
Q2
$19M Buy
596,295
+33,962
+6% +$1.11M 0.17% 60
2015
Q1
$18.6M Buy
562,333
+24,424
+5% +$777K 0.17% 59
2014
Q4
$15.9M Buy
537,909
+23,634
+5% +$678K 0.17% 61
2014
Q3
$14.4M Buy
514,275
+29,346
+6% +$824K 0.17% 65
2014
Q2
$13.7M Buy
484,929
+43,182
+10% +$1.23M 0.18% 62
2014
Q1
$13.5M Buy
441,747
+12,799
+3% +$382K 0.2% 54
2013
Q4
$12.5M Sell
428,948
-69,722
-14% -$2.03M 0.21% 57
2013
Q3
$13.6M Buy
498,670
+15,918
+3% +$433K 0.27% 44
2013
Q2
$12.8M Buy
+482,752
New +$13.3M 0.3% 41

Other funds holding PFE

Creative Planning's PFE Position: Q1 2026 in Review

Creative Planning increased its Pfizer (PFE) stake by 15% in Q1 2026, buying an estimated $7.24M and bringing the position to 2,122,972 shares worth $59.6M. The position accounts for 0.04% of the portfolio, ranked #187.

Creative Planning first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.6M in Q4 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Creative Planning held 2,122,972 shares of Pfizer worth $59.6M as of Q1 2026.
  • Creative Planning bought 271,983 Pfizer shares in Q1 2026, an estimated $7.24M.
  • Pfizer made up 0.04% of Creative Planning's portfolio in Q1 2026, its #187 holding.
  • Creative Planning first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Pfizer position peaked at $68.6M in Q4 2022.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.